0001213900-23-004081.txt : 20230120
0001213900-23-004081.hdr.sgml : 20230120
20230120160014
ACCESSION NUMBER: 0001213900-23-004081
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230119
FILED AS OF DATE: 20230120
DATE AS OF CHANGE: 20230120
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Shefferman Jesse
CENTRAL INDEX KEY: 0001799167
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36694
FILM NUMBER: 23540915
MAIL ADDRESS:
STREET 1: C/O ARTARA THERAPEUTICS,INC.
STREET 2: 1 LITTLE WEST 12TH STREET
CITY: NEW YORK
STATE: NY
ZIP: 10014
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Protara Therapeutics, Inc.
CENTRAL INDEX KEY: 0001359931
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 204580525
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 345 PARK AVENUE SOUTH
STREET 2: 3RD FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10010
BUSINESS PHONE: 646-844-0337
MAIL ADDRESS:
STREET 1: 345 PARK AVENUE SOUTH
STREET 2: 3RD FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10010
FORMER COMPANY:
FORMER CONFORMED NAME: ArTara Therapeutics, Inc.
DATE OF NAME CHANGE: 20200110
FORMER COMPANY:
FORMER CONFORMED NAME: PROTEON THERAPEUTICS INC
DATE OF NAME CHANGE: 20060420
4
1
ownership.xml
X0306
4
2023-01-19
0
0001359931
Protara Therapeutics, Inc.
TARA
0001799167
Shefferman Jesse
C/O PROTARA THERAPEUTICS, INC.
345 PARK AVENUE SOUTH, 3RD FLOOR
NEW YORK
NY
10010
1
1
0
0
CEO and President
Common Stock
2023-01-19
4
A
0
51300
0.00
A
918282
D
Stock Option (Right to Buy)
3.02
2023-01-19
4
A
0
307500
0.00
A
2033-01-18
Common Stock
307500
307500
D
The shares being reported are being issued pursuant to restricted stock unit awards (RSUs), each of which represents a contingent right to receive one share of Issuer's common stock. The RSUs vest in equal one-third installments on the first, second and third anniversaries of January 19, 2023.
25% of the shares vest on the one year anniversary of January 19, 2023 and 1/48th of the shares vest monthly thereafter over the next three years, subject to the Reporting Person's continuous service with the Issuer as of each such date.
/s/ Mary Grendell, Attorney-In-Fact
2023-01-20